Cara Therapeutics reported $3.06M in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.14M 531K
Acelrx Pharmaceuticals ACRX:US USD 569K 307K
Aerie Pharmaceuticals AERI:US USD 6.93M 3.19M
Cara Therapeutics CARA:US USD 3.06M 3.06M
Chugai Pharma 4519:JP JPY 69.1B 10.73B
Depomed DEPO:US USD 4.01M 219K
Endo International Ordinary Shares ENDP:US USD 176.86M 1.06M
Halozyme Therapeutics HALO:US USD 47.32M 13.38M
Horizon Pharma HZNP:US USD 234.13M 3.92M
Johnson & Johnson JNJ:US USD 7.81B 95M
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Pacira Pharmaceuticals PCRX:US USD 50.68M 51K
Pfizer PFE:US USD 6.09B 2.58B
Revance Therapeutics RVNC:US USD 10.74M 1.21M
Supernus Pharmaceuticals SUPN:US USD 25.88M 5.42M
Teva Pharmaceutical Industries TEVA:US USD 1.88B 73M
Vanda Pharmaceuticals VNDA:US USD 6.32M 261K